Supernus Pharmaceuticals Financials

Values in thousands	2026-09-30	2026-06-30	2026-03-31	2025-12-31
Revenue	$226,771	$219,058	$207,705	$211,572
Gross Profit	199,753	185,389	184,314	188,565
EBITDA	47,054	-29,586	20,194	26,672
EBIT	23,427	-55,333	-5,950	1,656
Net Income	20,913	-58,371	-2,293	-4,105
Net Change In Cash	226,771	219,058	207,705	211,572
Free Cash Flow	6,376	-5,378	66,524	19,434
Cash	175,884	179,953	184,869	128,448
Basic Shares	59,471	58,070	57,647	57,344

Values in thousands	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	$718,952	$661,817	$607,521	$667,238
Gross Profit	644,390	583,911	523,742	580,017
EBITDA	42,533	178,284	90,043	153,356
EBIT	-49,030	97,870	5,184	67,813
Net Income	-38,550	73,865	1,316	60,711
Net Change In Cash	718,952	661,817	607,521	667,238
Cost of Revenue				-110,314
Free Cash Flow	45,993	171,226	110,534	116,414
Cash	128,448	69,331	75,054	93,120
Basic Shares	56,451	55,959	55,506	61,679